Viatris “continues to feel strongly that 2021 is our trough year” in terms of profitability but concedes that group revenue is a harder metric to pin down given several uncertainties and challenges, as the combination of Mylan and Pfizer’s Upjohn published its first full quarter of financial results and tentatively reaffirmed full-year 2021 financial guidance.
Viatris: 2021 Is Trough Year For Earnings But Revenues A Trickier Prospect
Company ‘Very, Very Pleased’ With Q1 Financials
Committed to greater transparency following its formation in November, Viatris published first-quarter financial results that met top- and bottom-line expectations. However, the US-based company promised to update the market for meeting revenue projections in 2021.
More from Earnings
More from Business
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.